The US Food and Drug Administration (FDA) has issued a conditional green light for US drug giant Pfizer’s novel antifungal, anidulafungin, but the company has declined to reveal the nature of the requirements it needs to satisfy before full approval will be granted, reports thestreet.com
Anidulafungin has been developed to fight fungal infections of the skin and mucous membrane that can enter the bloodstream and cause problems for the heart. Pfizer is seeking initial clearance to market the agent for fungal infections of the oesophagus.
